A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2016
At a glance
- Drugs Capecitabine (Primary) ; Gemcitabine (Primary)
- Indications Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 02 Jan 2013 Planned end date changed from 1 Dec 2014 to 1 Dec 2017 as reported by ClinicalTrials.gov.
- 03 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 26 May 2012 Additional lead trial investigator (Mary F. Mulcahy) identified as reported by Robert H. Lurie Comprehensive Cancer Center, Northwestern University record.